345 related articles for article (PubMed ID: 21177764)
61. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
Wise-Draper TM; Moorthy G; Salkeni MA; Karim NA; Thomas HE; Mercer CA; Beg MS; O'Gara S; Olowokure O; Fathallah H; Kozma SC; Thomas G; Rixe O; Desai P; Morris JC
Target Oncol; 2017 Jun; 12(3):323-332. PubMed ID: 28357727
[TBL] [Abstract][Full Text] [Related]
62. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Chan JA; Mayer RJ; Jackson N; Malinowski P; Regan E; Kulke MH
Cancer Chemother Pharmacol; 2013 May; 71(5):1241-6. PubMed ID: 23475104
[TBL] [Abstract][Full Text] [Related]
63. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Mita M; Fu S; Piha-Paul SA; Janku F; Mita A; Natale R; Guo W; Zhao C; Kurzrock R; Naing A
Invest New Drugs; 2017 Oct; 35(5):616-626. PubMed ID: 28194539
[TBL] [Abstract][Full Text] [Related]
64. A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA; Sica GL; Steuer CE; Shaib WL; Wu C; Harris WB; Akce M; Kudchagkar RR; El-Rayes BF; Lonial S; Ramalingam SS; Khuri FR
Clin Cancer Res; 2020 Jun; 26(11):2497-2505. PubMed ID: 32005746
[TBL] [Abstract][Full Text] [Related]
65. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
[TBL] [Abstract][Full Text] [Related]
66. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
Pearson AD; Federico SM; Aerts I; Hargrave DR; DuBois SG; Iannone R; Geschwindt RD; Wang R; Haluska FG; Trippett TM; Geoerger B
Oncotarget; 2016 Dec; 7(51):84736-84747. PubMed ID: 27713169
[TBL] [Abstract][Full Text] [Related]
67. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.
Nemunaitis J; Hochster HS; Lustgarten S; Rhodes R; Ebbinghaus S; Turner CD; Dodion PF; Mita MM
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):336-42. PubMed ID: 23615181
[TBL] [Abstract][Full Text] [Related]
68. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
[TBL] [Abstract][Full Text] [Related]
69. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
Strickler JH; Starodub AN; Jia J; Meadows KL; Nixon AB; Dellinger A; Morse MA; Uronis HE; Marcom PK; Zafar SY; Haley ST; Hurwitz HI
Cancer Chemother Pharmacol; 2012 Aug; 70(2):251-8. PubMed ID: 22744359
[TBL] [Abstract][Full Text] [Related]
70. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
Bendell JC; Jones SF; Hart L; Spigel DR; Lane CM; Earwood C; Infante JR; Barton J; Burris HA
Invest New Drugs; 2015 Feb; 33(1):187-93. PubMed ID: 25335932
[TBL] [Abstract][Full Text] [Related]
71. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
Wilky BA; Rudek MA; Ahmed S; Laheru DA; Cosgrove D; Donehower RC; Nelkin B; Ball D; Doyle LA; Chen H; Ye X; Bigley G; Womack C; Azad NS
Br J Cancer; 2015 Jan; 112(1):24-31. PubMed ID: 25268371
[TBL] [Abstract][Full Text] [Related]
72. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Curigliano G; Martin M; Jhaveri K; Beck JT; Tortora G; Fazio N; Maur M; Hubner RA; Lahner H; Donnet V; Ajipa O; Li Z; Blumenstein L; Andre F
Eur J Cancer; 2021 Jul; 151():49-62. PubMed ID: 33964572
[TBL] [Abstract][Full Text] [Related]
73. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
74. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838
[TBL] [Abstract][Full Text] [Related]
75. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.
Mahadevan D; Sutton GR; Arteta-Bulos R; Bowden CJ; Miller PJ; Swart RE; Walker MS; Haluska P; Munster PN; Marshall J; Hamid O; Kurzrock R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):467-73. PubMed ID: 24390424
[TBL] [Abstract][Full Text] [Related]
76. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
[TBL] [Abstract][Full Text] [Related]
77. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
Acevedo-Gadea C; Santin AD; Higgins SA; Urva S; Ratner E; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Abu-Khalaf MM
Int J Gynecol Cancer; 2014 Mar; 24(3):528-33. PubMed ID: 24557436
[TBL] [Abstract][Full Text] [Related]
78. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.
Campone M; Levy V; Bourbouloux E; Berton Rigaud D; Bootle D; Dutreix C; Zoellner U; Shand N; Calvo F; Raymond E
Br J Cancer; 2009 Jan; 100(2):315-21. PubMed ID: 19127256
[TBL] [Abstract][Full Text] [Related]
79. Everolimus in colorectal cancer.
Altomare I; Hurwitz H
Expert Opin Pharmacother; 2013 Mar; 14(4):505-13. PubMed ID: 23406528
[TBL] [Abstract][Full Text] [Related]
80. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
